Pfizer Starts Global Phase 2/3 EPIC-PEP Study of Novel COVID-19 Oral Antiviral Candidate for Post-Exposure Prophylaxis in Adults Pharmaceutical Investing
Pfizer and OPKO Announce Extension of U.S. FDA Review of Biologics License Application of Somatrogon for Pediatric Growth Hormone Deficiency Pharmaceutical Investing
Knight Therapeutics Inc. places No. 27 on The Globe and Mail's third-annual ranking of Canada's Top Growing Companies Medical Device Investing
LYNPARZA® in Combination With Abiraterone Significantly Delayed Disease Progression in Patients Regardless of Biomarker Status in PROpel Phase 3 Trial in First-Line Metastatic Castration-Resistant Prostate Cancer Pharmaceutical Investing
Pfizer Invites Public to View and Listen to Webcast of Pfizer November 2 Conference Call with Analysts Pharmaceutical Investing
AbbVie Presents New Data Analyses for Growing Dermatology Portfolio at the 30th European Academy of Dermatology and Venereology Congress Biotech Investing
Knight Therapeutics Enters into Exclusive Supply and Distribution Agreement with Incyte for Tafasitamab and Pemigatinib in Latin America Medical Device Investing
BELLUS Health Announces Completion of Patient Enrollment in SOOTHE Phase 2b Trial for Refractory Chronic Cough and BLUEPRINT Phase 2a Trial for Chronic Pruritus Associated with Atopic Dermatitis Biotech Investing
Pfizer and BioNTech Receive First U.S. FDA Emergency Use Authorization of a COVID-19 Vaccine Booster Pharmaceutical Investing
Veklury® Significantly Reduced Risk of Hospitalization in High-Risk Patients with COVID-19 Biotech Investing
